@misc{oai:repo.qst.go.jp:00063598,
 author = {岩川, 眞由美 and 中渡, 美也子 and 今留, 香織 and 中村, 悦子 and 酒井, 美奈子 and 大野, 達也 and 加藤, 真吾 and 大久保, 悠 and 今井, 高志 and 岩川 眞由美 and 中渡 美也子 and 今留 香織 and 中村 悦子 and 酒井 美奈子 and 大野 達也 and 加藤 眞吾 and 大久保 悠 and 今井 高志},
 month = {Oct},
 note = {Purpose: Our previous research suggested FGF2 expression change would be an indicator for the efficacy of radiotherapy. Here, we validated this finding using newly enrolled patients and further investigated the mechanism of individual tumor radiosensitivity related with the FGF2 expression.
Experimental design: Sixty-nine patients were recruited as a validation set for immunohistichemical FGF2 expression in tumor cells (FGF2-T), using biopsy samples taken before or one week after initiation of radiotherapy. We also investigated the expression of FGF2 in tumor stroma (FGF2-S), VEGF and CD31 in 98 patients.
Results: FGF2-T significantly increased (P = 0.0037), and the ratio change of FGF2-T was significantly related with better prognosis (P = 0.028). Only tumors with positive FGF2-S in pretreatment samples increased VEGF expression (P = 0.035).
Conclusions: We confirmed our previous report for FGF2-T expression change. We also found the relationship between FGF2-S and VEGF during radiotherapy. These findings are indicative of the importance of combination timing and strict selection of patients in molecular target therapy after standard-of-care treatment., 第68回日本癌学会学術総会},
 title = {子宮頸癌生検試料における放射線治療応答マーカーFGF２の発現},
 year = {2009}
}